Genetic testing before weight-loss surgery could soon identify which women will receive the greatest protection against breast cancer. This personalized approach emerges from evidence that a common genetic variant fundamentally alters how bariatric procedures influence cancer risk in obese women.
Analysis of 2,596 severely obese women followed for nearly 24 years revealed that carriers of the FTO rs9939609 risk allele (TA/AA genotypes) experienced a 47% reduction in breast cancer incidence after bariatric surgery compared to standard care. However, women without this genetic variant (TT genotype) showed no cancer protection from surgery whatsoever, with some data suggesting potential increased risk. The treatment-genotype interaction proved statistically significant, indicating these differences exceed chance variation.
This finding reshapes understanding of bariatric surgery's anti-cancer mechanisms. The FTO gene regulates appetite and metabolism, with risk variants promoting insulin resistance and obesity-related inflammation. Women carrying these variants may benefit most from surgery's metabolic reset, including dramatic improvements in insulin sensitivity that directly influence breast tissue biology. The research builds on emerging evidence that obesity-related cancers respond differently to interventions based on individual genetic architecture. Current surgical guidelines focus primarily on BMI thresholds and comorbidities, but these results suggest genetic profiling could optimize patient selection. However, the study's observational design limits causal inference, and the findings require validation in diverse populations before clinical integration. The work represents an early step toward precision oncology in bariatric medicine.